




Preclinical Antiviral Sponsors and Developers

Preclinical Antiviral Landscape: Sponsors & Developers*

- Biotech/Pharma (44%) and University/Research Institutes (50%) represent **94%** of **125** sponsors/developers for preclinical compound/indications.
 - As programs move towards Potential Candidate, the relative contribution of sponsors/developers shifts more towards Biotech/Pharma. This is consistent with the increased resources needed to prepare for regulatory submissions and entry into clinical development.
- Sponsors/Developers of preclinical antiviral compound/indications are located in **24** countries across **5** of the **6** WHO-Regions.
 - The majority (**87.5%**) are located in countries with high-income economies.
 - The remainder have upper-middle income (**8.3%**) or lower-middle income (**4.2%**) economies.
- The United States (WHO Americas; High income) and China (WHO Western Pacific; Upper-middle income) have the most representation at **48.8%** and **12.8%**, respectively.

*As of December 18, 2024; Includes preclinical compounds categorized as Hit, Early Lead, Late Lead, or Potential Candidate.


Preclinical Antiviral Compound/Indications by Sponsor/Developer Type (N=125)*



*As of December 18, 2024; Includes preclinical compounds categorized as Hit, Early Lead, Late Lead, or Potential Candidate. CRO: contract research organization.

Preclinical Antiviral Compound/Indications by Sponsor/Developer WHO-Region*


(COVID-19 only and Non-COVID-19; N=125)



- ▶ There are twice as many COVID-19-specific versus Non-COVID-19 preclinical compound/indications.
 - ▶ COVID-19-specific: 74 are located in 5 of the 6 WHO-Regions.
 - ▶ Non-COVID-19-specific: 51 are located in 3 of 6 WHO-Regions.
- ▶ The Americas and Western Pacific regions are primarily driven by the United States and China.

*As of December 18, 2024; Includes preclinical compounds categorized as Hit, Early Lead, Late Lead, or Potential Candidate.

Promising and Watch & Wait Clinical Antiviral Compound/Indications* by Country and World Bank Economy Class**



- ▶ The majority (**86%**) of sponsors/developers are located in countries with high-income economies.
 - ▶ The remainder are those with upper-middle income (**13.2%**) or lower-middle income (**0.8%**) economies.
- ▶ The United States (HI) and China (UMI) have the most representation across the **24** countries.

*As of December 18, 2024; Includes preclinical compounds categorized as Hit, Early Lead, Late Lead, or Potential Candidate;

**[World Bank country classifications by income level for 2024-2025](#); LMI: lower-middle income; UMI: upper-middle income; HI: high-income.

Disclaimer

The INTREPID Alliance is a not-for-profit consortium of innovative biopharmaceutical companies committed to accelerating antiviral research, aiming to ensure that we have a stronger pipeline and are better prepared for future pandemics.

As part of our efforts, the INTREPID Alliance maintains and publishes a centralized list of promising investigational candidate compounds, with the purpose of knowledge-sharing and to support better pandemic preparedness. These compounds have been selected based on objective, scientific criteria, using publicly available sources, and at arm's length from commercial influence of our member companies. See criteria listed in the report “Antiviral Clinical Development Landscape and Promising Clinical Compounds.” The designation of certain compounds as promising is based upon currently available information, and exclusively upon an assessment against these criteria.

“Promising” is not a promotional claim. Candidate compounds have not been assessed by regulatory authorities to be safe and efficacious for the treatment of disease in humans. Our content is designed to be factual, informative, and non-commercial. It is not designed or intended to advertise or promote any pharmaceutical product or therapy or to advance the commercial interests of any company.